Literature DB >> 32021577

Evaluation of the target dose coverage of stereotactic body radiotherapy for lung cancer using helical tomotherapy: A dynamic phantom study.

Masahide Saito1, Hidekazu Suzuki1, Naoki Sano1, Kazunari Ashizawa1, Kazuya Yoshizawa1, Yuki Shibata1, Koji Ueda1, Takafumi Komiyama1, Kan Marino1, Shinichi Aoki1, Ryo Saito1, Yoshiyasu Maehata1, Hiroshi Onishi1.   

Abstract

AIM: To evaluate the target dose coverage for lung stereotactic body radiotherapy (SBRT) using helical tomotherapy (HT) with the internal tumor volume (ITV) margin settings adjusted according to the degree of tumor motion.
BACKGROUND: Lung SBRT with HT may cause a dosimetric error when the target motion is large.
MATERIALS AND METHODS: Two lung SBRT plans were created using a tomotherapy planning station. Using these original plans, five plans with different ITV margins (4.0-20.0 mm for superior-inferior [SI] dimension) were generated. To evaluate the effects of respiratory motion on HT, an original dynamic motion phantom was developed. The respiratory wave of a healthy volunteer was used for dynamic motion as the typical tumor respiratory motion. Five patterns of motion amplitude that corresponded to five ITV margin sizes and three breathing cycles of 7, 14, and 28 breaths per minute were used. We evaluated the target dose change between a static delivery and a dynamic delivery with each motion pattern.
RESULTS: The target dose difference increased as the tumor size decreased and as the tumor motion increased. Although a target dose difference of <5 % was observed at ≤10 mm of tumor motion for each condition, a maximum difference of -9.94 % ± 7.10 % was observed in cases of small tumors with 20 mm of tumor motion under slow respiration.
CONCLUSIONS: Minimizing respiratory movement is recommended as much as possible for lung SBRT with HT, especially for cases involving small tumors.
© 2020 Greater Poland Cancer Centre. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Helical tomotherapy; Lung cancer; Respiratory motion management; SBRT

Year:  2020        PMID: 32021577      PMCID: PMC6994284          DOI: 10.1016/j.rpor.2020.01.001

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  27 in total

1.  A simple respiratory indicator for irradiation during voluntary breath holding: a one-touch device without electronic materials.

Authors:  Hiroshi Onishi; Hideyuki Kawakami; Kan Marino; Takafumi Komiyama; Kengo Kuriyama; Masayuki Araya; Ryo Saito; Shinichi Aoki; Tsutomu Araki
Journal:  Radiology       Date:  2010-06       Impact factor: 11.105

2.  A motion phantom study on helical tomotherapy: the dosimetric impacts of delivery technique and motion.

Authors:  Brian Kanagaki; Paul W Read; Janelle A Molloy; James M Larner; Ke Sheng
Journal:  Phys Med Biol       Date:  2006-12-18       Impact factor: 3.609

3.  Dosimetric impact of breathing motion in lung stereotactic body radiotherapy treatment using intensity modulated radiotherapy and volumetric modulated arc therapy [corrected].

Authors:  Min Rao; Jianzhou Wu; Daliang Cao; Tony Wong; Vivek Mehta; David Shepard; Jinsong Ye
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-02-24       Impact factor: 7.038

4.  A randomized Phase III trial of comparing two dose-fractionations stereotactic body radiotherapy (SBRT) for medically inoperable Stage IA non-small cell lung cancer or small lung lesions clinically diagnosed as primary lung cancer: Japan Clinical Oncology Group Study JCOG1408 (J-SBRT trial).

Authors:  Tomoki Kimura; Yasushi Nagata; Junko Eba; Shuichi Ozawa; Satoshi Ishikura; Taro Shibata; Yoshinori Ito; Masahiro Hiraoka; Yasumasa Nishimura
Journal:  Jpn J Clin Oncol       Date:  2017-01-09       Impact factor: 3.019

5.  Feasibility of real-time motion management with helical tomotherapy.

Authors:  Eric Schnarr; Matt Beneke; Dylan Casey; Edward Chao; Jonathan Chappelow; Andrea Cox; Doug Henderson; Petr Jordan; Etienne Lessard; Dan Lucas; Andriy Myronenko; Calvin Maurer
Journal:  Med Phys       Date:  2018-02-23       Impact factor: 4.071

6.  Experimentally studied dynamic dose interplay does not meaningfully affect target dose in VMAT SBRT lung treatments.

Authors:  Cassandra Stambaugh; Benjamin E Nelms; Thomas Dilling; Craig Stevens; Kujtim Latifi; Geoffrey Zhang; Eduardo Moros; Vladimir Feygelman
Journal:  Med Phys       Date:  2013-09       Impact factor: 4.071

7.  A technique for stereotactic radiosurgery treatment planning with helical tomotherapy.

Authors:  Emilie T Soisson; Peter W Hoban; Thomas Kammeyer; Jeffrey M Kapatoes; David C Westerly; Amar Basavatia; Wolfgang A Tomé
Journal:  Med Dosim       Date:  2011       Impact factor: 1.482

8.  Dosimetric impact of the interplay effect during stereotactic lung radiation therapy delivery using flattening filter-free beams and volumetric modulated arc therapy.

Authors:  Chin Loon Ong; Max Dahele; Ben J Slotman; Wilko F A R Verbakel
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-07-15       Impact factor: 7.038

9.  Tomotherapy: implications on daily workload and scheduling patients based on three years' institutional experience.

Authors:  T Piotrowski; E Czajka; B Bak; J Kazmierska; M Skorska; A Ryczkowski; M Adamczyk; A Jodda
Journal:  Technol Cancer Res Treat       Date:  2013-09-20

10.  Lung SBRT: dosimetric and delivery comparison of RapidArc, TomoTherapy, and IMR.

Authors:  Ashleigh Weyh; Andre Konski; Adrian Nalichowski; Jordan Maier; Danielle Lack
Journal:  J Appl Clin Med Phys       Date:  2013-07-08       Impact factor: 2.102

View more
  2 in total

1.  Dosimetric accuracy of three dose calculation algorithms for radiation therapy of in situ non-small cell lung carcinoma.

Authors:  Manda Švabić Kolacio; David Rajlić; Milan Radojčić; Đeni Smilović Radojčić; Nevena Obajdin; Dea Dundara Debeljuh; Slaven Jurković
Journal:  Rep Pract Oncol Radiother       Date:  2022-03-22

2.  Dosimetric Effects of Differences in Multi-Leaf Collimator Speed on SBRT-VMAT for Central Lung Cancer Patients.

Authors:  Masahide Saito; Takafumi Komiyama; Kan Marino; Shinichi Aoki; Mitsuhiko Oguri; Takashi Yamada; Naoki Sano; Hidekazu Suzuki; Koji Ueda; Hiroshi Onishi
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.